Omega-3 fatty acids and major depression: a Mendelian randomization study.
Humans
Mendelian Randomization Analysis
Depressive Disorder, Major
/ genetics
Fatty Acids, Omega-3
/ blood
Genome-Wide Association Study
Female
Male
Polymorphism, Single Nucleotide
Middle Aged
Eicosapentaenoic Acid
/ blood
Docosahexaenoic Acids
/ blood
Delta-5 Fatty Acid Desaturase
Fatty Acid Desaturases
/ genetics
Adult
Fatty Acids, Omega-6
/ blood
Aged
United Kingdom
/ epidemiology
Journal
Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664
Informations de publication
Date de publication:
29 May 2024
29 May 2024
Historique:
received:
22
03
2022
accepted:
15
05
2024
revised:
10
05
2024
medline:
30
5
2024
pubmed:
30
5
2024
entrez:
29
5
2024
Statut:
epublish
Résumé
Omega-3 fatty acids have been implicated in the aetiology of depressive disorders, though trials supplementing omega-3 to prevent major depressive disorder (MDD) have so far been unsuccessful. Whether this association is causal remains unclear. We used two sample Mendelian randomization (MR) to investigate causality. Genetic variants associated with circulating omega-3 and omega-6 fatty acids in UK Biobank (UKBB, n = 115,078) were selected as exposures. The Psychiatric Genomics Consortium (PGC) genome-wide association studies (GWAS) of MDD (n = 430,775; cases = 116,209; controls = 314,566) and recurrent depression (rMDD, n = 80,933; cases = 17,451; controls = 62,482), were used as outcomes. Multivariable MR (MVMR) models were used to account for biologically correlated lipids, such as high- and low-density cholesterol and triglycerides, and to explore the relative importance of longer-chain omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) using data from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE, n = 8866). Genetic colocalization analyses were used to explore the presence of a shared underlying causal variant between traits. Genetically predicted total omega-3 fatty acids reduced the odds of MDD (OR
Identifiants
pubmed: 38811538
doi: 10.1038/s41398-024-02932-w
pii: 10.1038/s41398-024-02932-w
doi:
Substances chimiques
Fatty Acids, Omega-3
0
Eicosapentaenoic Acid
AAN7QOV9EA
Docosahexaenoic Acids
25167-62-8
Delta-5 Fatty Acid Desaturase
0
Fatty Acid Desaturases
EC 1.14.19.-
FADS2 protein, human
EC 1.14.19.3
FADS1 protein, human
EC 1.14.19.3
Fatty Acids, Omega-6
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
222Subventions
Organisme : Wellcome Trust (Wellcome)
ID : 212557/Z/18/Z
Organisme : RCUK | Medical Research Council (MRC)
ID : MR/P014054/1
Organisme : RCUK | Medical Research Council (MRC)
ID : MC_UU_00011/1, MC_UU_00011/3, MC_UU_00011/6, and MC_UU_00011/4
Organisme : RCUK | Medical Research Council (MRC)
ID : MC_UU_00011/1, MC_UU_00011/3, MC_UU_00011/6, and MC_UU_00011/4
Organisme : Cancer Research UK (CRUK)
ID : C18281/A29019
Organisme : RCUK | MRC | Medical Research Foundation
ID : MC_UU_00011/1, MC_UU_00011/3, MC_UU_00011/6, and MC_UU_00011/4
Organisme : RCUK | MRC | Medical Research Foundation
ID : MC_UU_00011/1, MC_UU_00011/3, MC_UU_00011/6, and MC_UU_00011/4
Organisme : DH | National Institute for Health Research (NIHR)
ID : NIHR202411
Informations de copyright
© 2024. The Author(s).
Références
Surette ME. The science behind dietary omega-3 fatty acids. CMAJ. 2008;178:177–80.
pubmed: 18195292
pmcid: 2174995
doi: 10.1503/cmaj.071356
Bazinet RP, Laye S. Polyunsaturated fatty acids and their metabolites in brain function and disease. Nat Rev Neurosci. 2014;15:771–85.
pubmed: 25387473
doi: 10.1038/nrn3820
Dighriri IM, Alsubaie AM, Hakami FM, Hamithi DM, Alshekh MM, Khobrani FA, et al. Effects of omega-3 polyunsaturated fatty acids on brain functions: a systematic review. Cureus. 2022;14:e30091.
pubmed: 36381743
pmcid: 9641984
Troesch B, Eggersdorfer M, Laviano A, Rolland Y, Smith AD, Warnke I, et al. Expert opinion on benefits of long-chain omega-3 fatty acids (DHA and EPA) in aging and clinical nutrition. Nutrients. 2020;12:1070.
doi: 10.3390/nu12092555
Wagner A, Simon C, Morio B, Dallongeville J, Ruidavets JB, Haas B, et al. Omega-3 index levels and associated factors in a middle-aged French population: the MONA LISA-NUT Study. Eur J Clin Nutr. 2015;69:436–41.
pubmed: 25335443
doi: 10.1038/ejcn.2014.219
Das UN. Essential fatty acids: biochemistry, physiology and pathology. Biotechnol J. 2006;1:420–39.
pubmed: 16892270
doi: 10.1002/biot.200600012
Mongan D, Healy C, Jones HJ, Zammit S, Cannon M, Cotter DR. Plasma polyunsaturated fatty acids and mental disorders in adolescence and early adulthood: cross-sectional and longitudinal associations in a general population cohort. Transl Psychiatry. 2021;11:321.
pubmed: 34059620
pmcid: 8167090
doi: 10.1038/s41398-021-01425-4
Berger ME, Smesny S, Kim SW, Davey CG, Rice S, Sarnyai Z, et al. Omega-6 to omega-3 polyunsaturated fatty acid ratio and subsequent mood disorders in young people with at-risk mental states: a 7-year longitudinal study. Transl Psychiatry. 2017;7:e1220.
pubmed: 28850110
pmcid: 5611753
doi: 10.1038/tp.2017.190
Li Z, Ruan M, Chen J, Fang Y. Major depressive disorder: advances in neuroscience research and translational applications. Neurosci Bull. 2021;37:863–80.
pubmed: 33582959
pmcid: 8192601
doi: 10.1007/s12264-021-00638-3
Appleton KM, Voyias PD, Sallis HM, Dawson S, Ness AR, Churchill R, et al. Omega-3 fatty acids for depression in adults. Cochrane Database Syst Rev. 2021;11:CD004692.
pubmed: 34817851
Lin PY, Huang SY, Su KP. A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression. Biol Psychiatry. 2010;68:140–7.
pubmed: 20452573
doi: 10.1016/j.biopsych.2010.03.018
Thesing CS, Milaneschi Y, Bot M, Brouwer IA, Owens M, Hegerl U, et al. Supplementation-induced increase in circulating omega-3 serum levels is not associated with a reduction in depressive symptoms: Results from the MooDFOOD depression prevention trial. Depress Anxiety. 2020;37:1079–88.
pubmed: 32845021
pmcid: 7693241
doi: 10.1002/da.23092
Deane KHO, Jimoh OF, Biswas P, O’Brien A, Hanson S, Abdelhamid AS, et al. Omega-3 and polyunsaturated fat for prevention of depression and anxiety symptoms: systematic review and meta-analysis of randomised trials. Br J Psychiatry. 2021;218:135–42.
pubmed: 31647041
doi: 10.1192/bjp.2019.234
Wolters M, von der Haar A, Baalmann AK, Wellbrock M, Heise TL, Rach S. Effects of n-3 polyunsaturated fatty acid supplementation in the prevention and treatment of depressive disorders—a systematic review and meta-analysis. Nutrients. 2021;13:1070.
pubmed: 33806078
pmcid: 8064470
doi: 10.3390/nu13041070
Okereke OI, Vyas CM, Mischoulon D, Chang G, Cook NR, Weinberg A, et al. Effect of long-term supplementation with marine omega-3 fatty acids vs. placebo on risk of depression or clinically relevant depressive symptoms and on change in mood scores: a randomized clinical trial. JAMA. 2021;326:2385–94.
pubmed: 34932079
pmcid: 8693224
doi: 10.1001/jama.2021.21187
Guu TW, Mischoulon D, Sarris J, Hibbeln J, McNamara RK, Hamazaki K, et al. International Society for Nutritional Psychiatry Research Practice Guidelines for omega-3 fatty acids in the treatment of major depressive disorder. Psychother Psychosom. 2019;88:263–73.
pubmed: 31480057
doi: 10.1159/000502652
Grosso G, Pajak A, Marventano S, Castellano S, Galvano F, Bucolo C, et al. Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials. PLoS ONE. 2014;9:e96905.
pubmed: 24805797
pmcid: 4013121
doi: 10.1371/journal.pone.0096905
Kelaiditis CF, Gibson EL, Dyall SC. Effects of long-chain omega-3 polyunsaturated fatty acids on reducing anxiety and/or depression in adults; A systematic review and meta-analysis of randomised controlled trials. Prostaglandins Leukot Essent Fatty Acids. 2023;192:102572.
pubmed: 37028202
doi: 10.1016/j.plefa.2023.102572
Albert BB, Cameron-Smith D, Hofman PL, Cutfield WS. Oxidation of marine omega-3 supplements and human health. Biomed Res Int. 2013;2013:464921.
pubmed: 23738326
pmcid: 3657456
doi: 10.1155/2013/464921
Carnegie R, Zheng J, Sallis HM, Jones HJ, Wade KH, Evans J, et al. Mendelian randomisation for nutritional psychiatry. Lancet Psychiatry. 2020;7:208–16.
pubmed: 31759900
doi: 10.1016/S2215-0366(19)30293-7
Zheng J, Baird D, Borges MC, Bowden J, Hemani G, Haycock P, et al. Recent developments in Mendelian randomization studies. Curr Epidemiol Rep. 2017;4:330–45.
pubmed: 29226067
pmcid: 5711966
doi: 10.1007/s40471-017-0128-6
Sallis H, Steer C, Paternoster L, Smith GD, Evans J. Perinatal depression and omega-3 fatty acids: a Mendelian randomisation study. J Affect Disord. 2014;166:124–31.
pubmed: 25012420
pmcid: 4101243
doi: 10.1016/j.jad.2014.04.077
Milaneschi Y, Peyrot WJ, Nivard MG, Mbarek H, Boomsma DI, Penninx BWJH. A role for vitamin D and omega-3 fatty acids in major depression? An exploration using genomics. Transl Psychiatry. 2019;9:219.
pubmed: 31488809
pmcid: 6728377
doi: 10.1038/s41398-019-0554-y
Borges MC, Haycock PC, Zheng J, Hemani G, Holmes MV, Davey Smith G, et al. Role of circulating polyunsaturated fatty acids on cardiovascular diseases risk: analysis using Mendelian randomization and fatty acid genetic association data from over 114,000 UK Biobank participants. BMC Med. 2022;20:210.
pubmed: 35692035
pmcid: 9190170
doi: 10.1186/s12916-022-02399-w
Howard DM, Adams MJ, Clarke TK, Hafferty JD, Gibson J, Shirali M, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nat Neurosci. 2019;22:343–52.
pubmed: 30718901
pmcid: 6522363
doi: 10.1038/s41593-018-0326-7
Coleman JRI, Gaspar HA, Bryois J, Breen G. The genetics of the mood disorder spectrum: genome-wide association analyses of over 185,000 cases and 439,000 controls. Biol Psychiatry. 2020;88:169–84.
pubmed: 31926635
doi: 10.1016/j.biopsych.2019.10.015
Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet. 2018;50:668–81.
pubmed: 29700475
pmcid: 5934326
doi: 10.1038/s41588-018-0090-3
Team RC. R: a language and environment for statistical computing. vol. 361. Vienna, Austria: R Foundation for Statistical Computing; 2019.
Elsworth B, Lyon M, Alexander T, Liu Y, Matthews P, Hallett J, et al. The MRC IEU OpenGWAS data infrastructure. bioRxiv https://doi.org/10.1101/2020.08.10.244293 [Preprint]. 2020.
Hemani G, Zhengn J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018;7:e34408.
pubmed: 29846171
pmcid: 5976434
doi: 10.7554/eLife.34408
Wickham H. ggplot2: elegant graphics for data analysis. New York: Springer-Verlag; 2016.
Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS Genet. 2017;13:e1007081.
pubmed: 29149188
pmcid: 5711033
doi: 10.1371/journal.pgen.1007081
Jones HJ, Borges MC, Carnegie R, Mongan D, Rogers PJ, Lewis SJ, et al. Associations between plasma fatty acid concentrations and schizophrenia: a two-sample Mendelian randomisation study. Lancet Psychiatry. 2021;8:1062–70.
pubmed: 34735824
doi: 10.1016/S2215-0366(21)00286-8
Burgess S, Freitag DF, Khan H, Gorman DN, Thompson SG. Using multivariable Mendelian randomization to disentangle the causal effects of lipid fractions. PLoS ONE. 2014;9:e108891.
pubmed: 25302496
pmcid: 4193746
doi: 10.1371/journal.pone.0108891
Sanderson E, Spiller W, Bowden J. Testing and correcting for weak and pleiotropic instruments in two-sample multivariable Mendelian randomization. Stat Med. 2021;40:5434–52.
pubmed: 34338327
pmcid: 9479726
doi: 10.1002/sim.9133
Wallace C. Eliciting priors and relaxing the single causal variant assumption in colocalisation analyses. PLoS Genet. 2020;16:e1008720.
pubmed: 32310995
pmcid: 7192519
doi: 10.1371/journal.pgen.1008720
Burgess S, Davies NM, Thompson SG. Bias due to participant overlap in two-sample Mendelian randomization. Genet Epidemiol. 2016;40:597–608.
pubmed: 27625185
pmcid: 5082560
doi: 10.1002/gepi.21998
Sadreev II, Elsworth BL, Mitchell RE, Paternoster L, Sanderson E, Davies NM, et al. Navigating sample overlap, winner’s curse and weak instrument bias in Mendelian randomization studies using the UK Biobank. medRxiv. https://doi.org/10.1101/2021.06.28.21259622 [Preprint].
Roke K, Mutch DM. The role of FADS1/2 polymorphisms on cardiometabolic markers and fatty acid profiles in young adults consuming fish oil supplements. Nutrients. 2014;6:2290–304.
pubmed: 24936800
pmcid: 4073151
doi: 10.3390/nu6062290
Steer CD, Davey Smith G, Emmett PM, Hibbeln JR, Golding J. FADS2 polymorphisms modify the effect of breastfeeding on child IQ. PLoS ONE. 2010;5:e11570.
pubmed: 20644632
pmcid: 2903485
doi: 10.1371/journal.pone.0011570
Cribb L, Murphy J, Froud A, Oliver G, Bousman CA, Ng CH, et al. Erythrocyte polyunsaturated fatty acid composition is associated with depression and FADS genotype in Caucasians. Nutr Neurosci. 2018;21:589–601.
pubmed: 28552045
doi: 10.1080/1028415X.2017.1327685
Sublette ME, Vaquero C, Baca-Garcia E, Pachano G, Huang YY, Oquendo MA, et al. Lack of association of SNPs from the FADS1-FADS2 gene cluster with major depression or suicidal behavior. Psychiatr Genet. 2016;26:81–6.
pubmed: 26513616
pmcid: 4764474
doi: 10.1097/YPG.0000000000000111
Wang X, Verma S, Mason RP, Bhatt DL. The road to approval: a perspective on the role of icosapent ethyl in cardiovascular risk reduction. Curr Diab Rep. 2020;20:65.
pubmed: 33095318
pmcid: 7584545
doi: 10.1007/s11892-020-01343-7
Bazinet RP, Metherel AH, Chen CT, Shaikh SR, Nadjar A, Joffre C, et al. Brain eicosapentaenoic acid metabolism as a lead for novel therapeutics in major depression. Brain Behav Immun. 2020;85:21–8.
pubmed: 31278982
doi: 10.1016/j.bbi.2019.07.001
Crupi R, Cuzzocrea S. Role of EPA in inflammation: mechanisms, effects, and clinical relevance. Biomolecules. 2022;12:242.
pubmed: 35204743
pmcid: 8961629
doi: 10.3390/biom12020242
So J, Wu D, Lichtenstein AH, Tai AK, Matthan NR, Maddipati KR, et al. EPA and DHA differentially modulate monocyte inflammatory response in subjects with chronic inflammation in part via plasma specialized pro-resolving lipid mediators: a randomized, double-blind, crossover study. Atherosclerosis. 2021;316:90–8.
pubmed: 33303222
doi: 10.1016/j.atherosclerosis.2020.11.018
Trepanier MO, Hopperton KE, Orr SK, Bazinet RP. N-3 polyunsaturated fatty acids in animal models with neuroinflammation: an update. Eur J Pharmacol. 2016;785:187–206.
pubmed: 26036964
doi: 10.1016/j.ejphar.2015.05.045
Lemaitre RN, Tanaka T, Tang W, Manichaikul A, Foy M, Kabagambe EK, et al. Genetic loci associated with plasma phospholipid n-3 fatty acids: a meta-analysis of genome-wide association studies from the CHARGE Consortium. PLoS Genet. 2011;7:e1002193.
pubmed: 21829377
pmcid: 3145614
doi: 10.1371/journal.pgen.1002193
Borges MC, Haycock P, Zheng J, Hemani G, Hingorani A, Lawlor DA. Role of circulating polyunsaturated fatty acids on cardiovascular diseases risk: analysis using Mendelian randomization and fatty acid genetic association data from over 114,000 UK Biobank participants. BMC Med. 2022;20:210.
pubmed: 35692035
pmcid: 9190170
doi: 10.1186/s12916-022-02399-w
Richardson TG, Sanderson E, Palmer TM, Ala-Korpela M, Ference BA, Davey Smith G, et al. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis. PLoS Med. 2020;17:e1003062.
pubmed: 32203549
pmcid: 7089422
doi: 10.1371/journal.pmed.1003062